{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T14:03:17Z","timestamp":1793628197000,"version":"4.5.1"},"reference-count":49,"publisher":"American Medical Association (AMA)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Neurol"],"published-print":{"date-parts":[[2022,3,1]]},"DOI":"10.1001\/jamaneurol.2021.5205","type":"journal-article","created":{"date-parts":[[2022,1,31]],"date-time":"2022-01-31T11:33:47Z","timestamp":1643628827000},"page":"291","source":"Crossref","is-referenced-by-count":183,"title":["Amyloid-Related Imaging Abnormalities and \u03b2-Amyloid\u2013Targeting Antibodies"],"prefix":"10.1001","volume":"79","author":[{"given":"Massimo","family":"Filippi","sequence":"first","affiliation":[{"name":"Neurology Unit, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Ospedale San Raffaele, Milan, Italy"},{"name":"Neurorehabilitation Unit, IRCCS Ospedale San Raffaele, Milan, Italy"},{"name":"Neurophysiology Service, IRCCS Ospedale San Raffaele, Milan, Italy"},{"name":"Neuroimaging Research Unit, Division of Neuroscience, IRCCS Ospedale San Raffaele, Milan, Italy"},{"name":"Vita-Salute San Raffaele University, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giordano","family":"Cecchetti","sequence":"additional","affiliation":[{"name":"Neurology Unit, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Ospedale San Raffaele, Milan, Italy"},{"name":"Neurophysiology Service, IRCCS Ospedale San Raffaele, Milan, Italy"},{"name":"Neuroimaging Research Unit, Division of Neuroscience, IRCCS Ospedale San Raffaele, Milan, Italy"},{"name":"Vita-Salute San Raffaele University, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edoardo Gioele","family":"Spinelli","sequence":"additional","affiliation":[{"name":"Neurology Unit, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Ospedale San Raffaele, Milan, Italy"},{"name":"Neuroimaging Research Unit, Division of Neuroscience, IRCCS Ospedale San Raffaele, Milan, Italy"},{"name":"Vita-Salute San Raffaele University, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Vezzulli","sequence":"additional","affiliation":[{"name":"Neuroradiology Unit and CERMAC (Centro Eccellenza Risonanza Magnetica ad Alto Campo), Division of Neuroscience, IRCCS Ospedale San Raffaele, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Falini","sequence":"additional","affiliation":[{"name":"Vita-Salute San Raffaele University, Milan, Italy"},{"name":"Neuroradiology Unit and CERMAC (Centro Eccellenza Risonanza Magnetica ad Alto Campo), Division of Neuroscience, IRCCS Ospedale San Raffaele, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Agosta","sequence":"additional","affiliation":[{"name":"Neurology Unit, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Ospedale San Raffaele, Milan, Italy"},{"name":"Neuroimaging Research Unit, Division of Neuroscience, IRCCS Ospedale San Raffaele, Milan, Italy"},{"name":"Vita-Salute San Raffaele University, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"2","key":"nrv210007r2","doi-asserted-by":"crossref","first-page":"111","DOI":"10.31887\/DCNS.2009.11.2\/cqiu","article-title":"Epidemiology of Alzheimer\u2019s disease: occurrence, determinants, and strategies toward intervention.","volume":"11","author":"Qiu","year":"2009","journal-title":"Dialogues Clin Neurosci"},{"issue":"1","key":"nrv210007r3","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s13195-017-0297-z","article-title":"Alzheimer\u2019s disease prevention: from risk factors to early intervention.","volume":"9","author":"Crous-Bou","year":"2017","journal-title":"Alzheimers Res Ther"},{"issue":"5","key":"nrv210007r4","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1097\/JOM.0000000000001229","article-title":"Costs and burden associated with loss of labor productivity in informal caregivers of people with dementia: results from Spain.","volume":"60","author":"Farr\u00e9","year":"2018","journal-title":"J Occup Environ Med"},{"issue":"24","key":"nrv210007r5","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.1212\/WNL.0b013e3181c67808","article-title":"A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease.","volume":"73","author":"Salloway","year":"2009","journal-title":"Neurology"},{"issue":"4","key":"nrv210007r6","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.jalz.2011.05.2351","article-title":"Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer\u2019s Association Research Roundtable Workgroup.","volume":"7","author":"Sperling","year":"2011","journal-title":"Alzheimers Dement"},{"issue":"8","key":"nrv210007r7","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.3174\/ajnr.A3475","article-title":"An MRI rating scale for amyloid-related imaging abnormalities with edema or effusion.","volume":"34","author":"Barkhof","year":"2013","journal-title":"AJNR Am J Neuroradiol"},{"issue":"7","key":"nrv210007r8","first-page":"P253","article-title":"Validation of a simple severity scale for assessing ARIA-E.","volume":"13","author":"Bracoud","year":"2017","journal-title":"Alzheimers Dement"},{"issue":"S2","key":"nrv210007r9","doi-asserted-by":"crossref","DOI":"10.1002\/alz.041110","article-title":"Calibration of a simplified ARIA-E MRI severity scale suitable for clinical practice.","volume":"16","author":"Klein","year":"2020","journal-title":"Alzheimers Dement"},{"issue":"21","key":"nrv210007r10","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1212\/WNL.0b013e3181c34a7d","article-title":"The Microbleed Anatomical Rating Scale (MARS): reliability of a tool to map brain microbleeds.","volume":"73","author":"Gregoire","year":"2009","journal-title":"Neurology"},{"issue":"3","key":"nrv210007r11","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1111\/jon.2017.27.issue-3","article-title":"Validation of an MRI rating scale for amyloid-related imaging abnormalities.","volume":"27","author":"Bechten","year":"2017","journal-title":"J Neuroimaging"},{"issue":"10","key":"nrv210007r12","doi-asserted-by":"publisher","first-page":"1958","DOI":"10.3174\/ajnr.A3500","article-title":"MR imaging features of amyloid-related imaging abnormalities.","volume":"34","author":"Barakos","year":"2013","journal-title":"AJNR Am J Neuroradiol"},{"key":"nrv210007r14","doi-asserted-by":"crossref","first-page":"n160","DOI":"10.1136\/bmj.n160","article-title":"PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews.","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"3","key":"nrv210007r16","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.trci.2017.04.003","article-title":"Multiple-dose ponezumab for mild-to-moderate Alzheimer\u2019s disease: safety and efficacy.","volume":"3","author":"Landen","year":"2017","journal-title":"Alzheimers Dement (N Y)"},{"issue":"4","key":"nrv210007r17","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1312889","article-title":"Phase 3 trials of solanezumab for mild-to-moderate Alzheimer\u2019s disease.","volume":"370","author":"Doody","year":"2014","journal-title":"N Engl J Med"},{"issue":"4","key":"nrv210007r18","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1056\/NEJMoa1705971","article-title":"Trial of solanezumab for mild dementia due to Alzheimer\u2019s disease.","volume":"378","author":"Honig","year":"2018","journal-title":"N Engl J Med"},{"issue":"4","key":"nrv210007r19","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.3233\/JAD-160369","article-title":"A phase II, randomized, double-blind, placebo-controlled study of safety, pharmacokinetics, and biomarker results of subcutaneous bapineuzumab in patients with mild to moderate Alzheimer\u2019s disease.","volume":"54","author":"Brody","year":"2016","journal-title":"J Alzheimers Dis"},{"issue":"1","key":"nrv210007r20","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s13195-016-0177-y","article-title":"First-in-human safety and long-term exposure data for AAB-003 (PF-05236812) and biomarkers after intravenous infusions of escalating doses in patients with mild to moderate Alzheimer\u2019s disease.","volume":"8","author":"Delnomdedieu","year":"2016","journal-title":"Alzheimers Res Ther"},{"issue":"4","key":"nrv210007r21","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1056\/NEJMoa1304839","article-title":"Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer\u2019s disease.","volume":"370","author":"Salloway","year":"2014","journal-title":"N Engl J Med"},{"issue":"1","key":"nrv210007r22","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s13195-016-0189-7","article-title":"Bapineuzumab for mild to moderate Alzheimer\u2019s disease in two global, randomized, phase 3 trials.","volume":"8","author":"Vandenberghe","year":"2016","journal-title":"Alzheimers Res Ther"},{"issue":"3","key":"nrv210007r23","doi-asserted-by":"publisher","first-page":"689","DOI":"10.3233\/JAD-171157","article-title":"Long-term follow up of patients with mild-to-moderate Alzheimer\u2019s disease treated with bapineuzumab in a phase III, open-label, extension study.","volume":"64","author":"Salloway","year":"2018","journal-title":"J Alzheimers Dis"},{"issue":"1","key":"nrv210007r24","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s13195-016-0193-y","article-title":"Long-term safety and tolerability of bapineuzumab in patients with Alzheimer\u2019s disease in two phase 3 extension studies.","volume":"8","author":"Ivanoiu","year":"2016","journal-title":"Alzheimers Res Ther"},{"issue":"21","key":"nrv210007r25","doi-asserted-by":"publisher","first-page":"e1889","DOI":"10.1212\/WNL.0000000000005550","article-title":"ABBY: a phase 2 randomized trial of crenezumab in mild to moderate Alzheimer disease.","volume":"90","author":"Cummings","year":"2018","journal-title":"Neurology"},{"issue":"3","key":"nrv210007r26","doi-asserted-by":"publisher","first-page":"967","DOI":"10.3233\/JAD-200134","article-title":"Safety, tolerability, and pharmacokinetics of crenezumab in patients with mild-to-moderate Alzheimer\u2019s disease treated with escalating doses for up to 133 weeks.","volume":"76","author":"Guthrie","year":"2020","journal-title":"J Alzheimers Dis"},{"issue":"1","key":"nrv210007r27","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s13195-017-0318-y","article-title":"A phase III randomized trial of gantenerumab in prodromal Alzheimer\u2019s disease.","volume":"9","author":"Ostrowitzki","year":"2017","journal-title":"Alzheimers Res Ther"},{"issue":"suppl 7","key":"nrv210007r28","first-page":"P241","article-title":"Update on the safety and tolerability of gantenerumab in the ongoing open-label extension (OLE) of the Marguerite Road study in patients with mild Alzheimer's disease (AD) after approximately two years of study duration.","volume":"14","author":"Abi-Saab","year":"2018","journal-title":"Alzheimers Dement"},{"issue":"suppl 7","key":"nrv210007r29","first-page":"P241","article-title":"Update on the safety and tolerability of gantenerumab in the ongoing open-label extension of the Scarlet Road study in patients with prodromal Alzheimer's disease after approximately 2 years of study duration.","volume":"14","author":"Andjelkovic","year":"2018","journal-title":"Alzheimers Dement"},{"issue":"1","key":"nrv210007r30","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s13195-019-0559-z","article-title":"Gantenerumab reduces amyloid-\u00df plaques in patients with prodromal to moderate Alzheimer\u2019s disease: a PET substudy interim analysis.","volume":"11","author":"Klein","year":"2019","journal-title":"Alzheimers Res Ther"},{"issue":"7","key":"nrv210007r31","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1038\/s41591-021-01369-8","article-title":"A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer\u2019s disease.","volume":"27","author":"Salloway","year":"2021","journal-title":"Nat Med"},{"issue":"7618","key":"nrv210007r32","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/nature19323","article-title":"The antibody aducanumab reduces A\u00df plaques in Alzheimer\u2019s disease.","volume":"537","author":"Sevigny","year":"2016","journal-title":"Nature"},{"issue":"1","key":"nrv210007r33","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s13195-021-00813-8","article-title":"A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer\u2019s disease with lecanemab, an anti-A\u00df protofibril antibody.","volume":"13","author":"Swanson","year":"2021","journal-title":"Alzheimers Res Ther"},{"issue":"18","key":"nrv210007r34","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa2100708","article-title":"Donanemab in early Alzheimer\u2019s disease.","volume":"384","author":"Mintun","year":"2021","journal-title":"N Engl J Med"},{"issue":"3","key":"nrv210007r37","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/S1474-4422(12)70015-7","article-title":"Amyloid-related imaging abnormalities in patients with Alzheimer\u2019s disease treated with bapineuzumab: a retrospective analysis.","volume":"11","author":"Sperling","year":"2012","journal-title":"Lancet Neurol"},{"issue":"1","key":"nrv210007r38","first-page":"106","article-title":"Amyloid-related imaging abnormalities\u2013haemosiderin (ARIA-H) in patients with Alzheimer\u2019s disease treated with bapineuzumab: a historical, prospective secondary analysis.","volume":"87","author":"Arrighi","year":"2016","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"2","key":"nrv210007r39","doi-asserted-by":"publisher","first-page":"557","DOI":"10.3233\/JAD-160216","article-title":"Central review of amyloid-related imaging abnormalities in two phase III clinical trials of bapineuzumab in mild-to-moderate Alzheimer\u2019s disease patients.","volume":"57","author":"Ketter","year":"2017","journal-title":"J Alzheimers Dis"},{"issue":"4","key":"nrv210007r40","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.3233\/JAD-180675","article-title":"Clinical evaluation of amyloid-related imaging abnormalities in bapineuzumab phase III studies.","volume":"66","author":"Brashear","year":"2018","journal-title":"J Alzheimers Dis"},{"issue":"10","key":"nrv210007r41","doi-asserted-by":"publisher","first-page":"e877","DOI":"10.1212\/WNL.0000000000005060","article-title":"Biomarker pattern of ARIA-E participants in phase 3 randomized clinical trials with bapineuzumab.","volume":"90","author":"Liu","year":"2018","journal-title":"Neurology"},{"issue":"3","key":"nrv210007r42","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1007\/s00330-017-5022-6","article-title":"The value of subtraction MRI in detection of amyloid-related imaging abnormalities with oedema or effusion in Alzheimer\u2019s patients: an interobserver study.","volume":"28","author":"Martens","year":"2018","journal-title":"Eur Radiol"},{"issue":"4","key":"nrv210007r43","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.jalz.2011.05.2353","article-title":"Prevalence of asymptomatic vasogenic edema in pretreatment Alzheimer\u2019s disease study cohorts from phase 3 trials of semagacestat and solanezumab.","volume":"7","author":"Carlson","year":"2011","journal-title":"Alzheimers Dement"},{"key":"nrv210007r44","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.dadm.2016.02.004","article-title":"Amyloid-related imaging abnormalities from trials of solanezumab for Alzheimer\u2019s disease.","volume":"2","author":"Carlson","year":"2016","journal-title":"Alzheimers Dement (Amst)"},{"issue":"1","key":"nrv210007r45","article-title":"Symptomatic amyloid-related imaging abnormalities in an APOE e4\/e4 patient treated with aducanumab.","volume":"12","author":"VandeVrede","year":"2020","journal-title":"Alzheimers Dement (Amst)"},{"issue":"4","key":"nrv210007r46","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.biopsych.2017.08.010","article-title":"Anti\u2013amyloid-\u00df monoclonal antibodies for Alzheimer\u2019s disease: pitfalls and promise.","volume":"83","author":"van Dyck","year":"2018","journal-title":"Biol Psychiatry"},{"issue":"3","key":"nrv210007r47","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.neulet.2010.02.016","article-title":"Amyloid load in nondemented brains correlates with APOE e4.","volume":"473","author":"Caselli","year":"2010","journal-title":"Neurosci Lett"},{"issue":"1","key":"nrv210007r48","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s13195-020-00663-w","article-title":"Aducanumab, gantenerumab, BAN2401, and ALZ-801\u2014the first wave of amyloid-targeting drugs for Alzheimer\u2019s disease with potential for near term approval.","volume":"12","author":"Tolar","year":"2020","journal-title":"Alzheimers Res Ther"},{"issue":"4","key":"nrv210007r49","first-page":"398","article-title":"Aducanumab: appropriate use recommendations.","volume":"8","author":"Cummings","year":"2021","journal-title":"J Prev Alzheimers Dis"},{"key":"nrv210007r1","unstructured":"Alzheimer\u2019s Disease International. World Alzheimer Report 2019: attitudes to dementia. September 20, 2019. Accessed September 1, 2021. https:\/\/www.alzint.org\/resource\/world-alzheimer-report-2019\/"},{"key":"nrv210007r13","unstructured":"US Food and Drug Administration. FDA news release: FDA grants accelerated approval for Alzheimer\u2019s drug. June 7, 2021. Accessed August 1, 2021. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-grants-accelerated-approval-alzheimers-drug"},{"key":"nrv210007r15","unstructured":"Oxford Centre for Evidence-Based Medicine. Levels of evidence (March 2009). Accessed September 1, 2021.  https:\/\/www.cebm.ox.ac.uk\/resources\/levels-of-evidence\/oxford-centre-for-evidence-based-medicine-levels-of-evidence-march-2009"},{"key":"nrv210007r35","unstructured":"221AD301 phase 3 study of aducanumab (BIIB037) in early Alzheimer\u2019s disease (ENGAGE). ClinicalTrials.gov identifier: NCT02477800. Accessed September 1, 2021. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02477800"},{"key":"nrv210007r36","unstructured":"221AD302 phase 3 study of aducanumab (BIIB037) in early Alzheimer\u2019s disease (EMERGE). ClinicalTrials.gov identifier: NCT02484547. Accessed September 1, 2021. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02484547"}],"container-title":["JAMA Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/articlepdf\/2788269\/jamaneurology_filippi_2022_rv_210007_1646836667.31156.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,14]],"date-time":"2022-03-14T11:08:04Z","timestamp":1647256084000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/fullarticle\/2788269"}},"subtitle":["A Systematic Review"],"short-title":[],"issued":{"date-parts":[[2022,3,1]]},"references-count":49,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaneurol.2021.5205","relation":{},"ISSN":["2168-6149"],"issn-type":[{"value":"2168-6149","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3,1]]}}}